ZIM
SGNT

Zacks Investment Management’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History

Zacks Investment Management’s Portfolio SGNT Stock Details SGNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-17,490
Closed -$425K – 735
2015
Q2 		$425K Buy
17,490
+1,362
+8% +$32.6K 0.01% 466
2015
Q1 		$375K Buy
16,128
+6,416
+66% +$170K 0.01% 471
2014
Q4 		$244K Buy
+9,712
New +$285K 0.01% 554

Other funds holding SGNT

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
PCM
Penn Capital Management Philadelphia, Pennsylvania $1.58B AUM 81.2% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Zacks Investment Management's SGNT Position: Q3 2015 in Review

Zacks Investment Management sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q3 2015, closing a stake of 17,490 shares — an estimated $425K sold.

Zacks Investment Management first reported a position in SGNT in Q4 2014 and held it in 3 quarters. The position peaked at $425K in Q2 2015. 127 funds tracked by Wall St. Rank hold SGNT as of Q3 2015.

  • Zacks Investment Management reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q3 2015 after selling out during the quarter.
  • Zacks Investment Management sold 17,490 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q3 2015, an estimated $425K.
  • Zacks Investment Management first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q4 2014 and held it in 3 quarters.
  • Zacks Investment Management's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $425K in Q2 2015.
  • 127 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q3 2015.

Based on Zacks Investment Management's 13F filing for Q3 2015, filed 12 Nov 2015.